Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of EYP-1901 versus aflibercept for diabetic macular edema
MOH_2026-02-08_015640Phase 3Not yet recruiting
- Sponsor
- EyePoint Pharmaceuticals
- Start
- Jan 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic macular edema (DME) comparing EYP-1901 arm with Aflibercept arm (2 arms). Primary endpoint: Visual benefit comparability over 56 weeks. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
vorolanibaflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on MOH_2026-02-08_015640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-02-08_015640.